Figure 3. Subgroup analyses for overall survival after propensity score matching among patients treated with and without paclitaxel plus bevacizumab (PB). A: Patients with pleural lesion, pulmonary carcinomatous lymphangitis or both. B: Patients with three or more metastatic sites but without liver metastases. CI: Confidence interval; PB: paclitaxel and bevacizumab therapy.
